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STRAIN-LIMITED DEVELOPMENT OF TUMORS
OF THE PITUITARY GLAND IN MICE
RECEIVING ESTROGENS*
W. U. GARDNER AND L. C. STRONG
Hypophyseal tumors occur rarely in mice. Only one mouse
among 11,000 autopsied in Dr. Slye's laboratory showed a hypo-
physeal tumor.11 A chromophobe-cell adenoma of the pituitary
gland was reported in a mouse which had bilateral granulosa-cell
tumors of the ovaries.6 This animal also showed evidence of hyper-
estrogenic stimulation, as indicated by multiple mammary tumors
and uterine glandular cystic hyperplasia.
Generalized hypertrophy of the pituitary gland occurs fre-
quently in rats and mice receiving estrogens.9 Almost simultaneously
three groups of investigators reported hypophyseal adenomatous
hypertrophy or adenomas in rats or mice receiving estrogens in large
amounts over long periods.'2 On the other hand, such tumors were
not observed among 111 mice of 3 different strains (A, CBA, and
C3H) given estrogens,4 while, in another laboratory,l one tumor
was found among 679 mice. Lacassagne'0 ascribed an initial failure
to observe hypophyseal lesions to a contamination of the "folliculin"
benzoate he used with equilin or equilenin. Recently, Zondek'4
described large tumors of the pituitary gland in rats given large
amounts of estrogens over a period of from 7 to 9 months. Some
of these tumors weighed more than 300 mg.
Materials
Over 800 mice from 7 different strains (A, C3H, CBA, C12L, C57, N,
and JK) have received estrogens in amounts of 8.3y to 250y weekly for
variable periods determined by the time of death or appearance of mammary,
uterine, lymphoid, or spindle-celled tumors. Estrone benzoate, estradiol
benzoate, estradiol dipropionate, equilin, equilin- and equilenin-benzoate, tri-
phenylethylene, and stilbestrol were the estrogenic chemicals used.t All the
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estrogens were dissolved in sesame oil and injected subcutaneously. In addi-
tion, other mice were given estrogens and testosterone propionate simul-
taneously. The pituitary glands were removed from the opened skulls either
before or after fixation in 10 per cent formalin, and when in 80 per cent
alcohol weighed on a torsion balance sensitive to 0.5 mg. After many obser-
vations had been made only those glands showing evidence of grossly apparent
hypertrophy were weighed. The tissues were sectioned at 5 micra and stained
with hematoxylin-eosin or iron hematoxylin-Mallory triple connective-tissue
stain (Crooke's modification).2
Observations
The pituitary glands of mice of all the strains studied increased
in size and showed a degranulation of the basophilic cells following
the injection of estrogens. The glands of the mice of 6 strains
which received estrogens (A, C3H, CBA, C12I, N, and JK) usually
weighed from 2 to 3 mg. and seldom weighed more than 4 mg.
(from 1.5 to 3 times the weight of glands of untreated mice).
Rarely were glands found that weighed 6 mg. In one mouse from
the C3H strain the pituitary body weighed 8.5 mg. The slightly or
more extensively enlarged glands of these strains were always uni-
form in shape and regular in outline. Many of the mice of these
strains received estrogens for more than 300 days. In the C12I, N,
and JK strains few animals tolerated treatment for longer periods.
The predominant structural changes were a slight enlargement of
the vascular sinuses, an increase in the non-granular cells, and a
marked decrease in granular basophilic cells.
Fourteen ofthe 68 mice of the C57 strain receiving weekly injec-
tions of from 8.3y to 16.6y of estradiol benzoate or 250y of stil-
bestrol had, at autopsy, pituitary glands weighing 12 mg. or more
(Table 1). This weight of 12 mg. was arbitrarily selected and
represented an increase of at least 6 times in the weight of the pitui-
tary body. Several mice had hypophyses weighing 5 to 11 mg.
One of 14 mice given weekly injections of 16.6y of estradiol ben-
zoate and 1.25 mg. of testosterone propionate also developed a
hypophyseal tumor. The hypophyses of 24 other mice of the same
strain which had received 50y of estradiol benzoate or estradiol
dipropionate weekly were not appreciably enlarged.
As some of the mice were not autopsied until some time after
death satisfactory histological observations could not be made on all
animals. The pituitary bodies weighing 26 mg. or less showed
hyperplasia of the chromophobic cells particularly. These changes
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TABLE 1
THE AVERAGE SURVIVAL AND INCIDENCE OF PITUITARY HYPERTROPHIES EXCEEDING
12 MG. OR ADENOMAS IN MICE OF THE C57 STRAIN RECEIVING ESTROGENS
Averagesof mice
withpituitary
Average No. of lesions
Number Periiod Age at pituitaries Period Age at
of mice treated; death; exceeding treated; death;
Chemical and sex days days 12 mg. days days
Estradiol dipro- 4M 65 132 .... ...... ......
pionate-50y wkly. 6 F 92 163 .... ...... ......
Estradiol ben- 6 M 165 203 .... ...... ......
zoate 50y wkly. 8 F 106 141 .... ...... ......
Estradiol ben- 32 M 242 282 9 323 366
zoate-16.6y wkly. 18 F 185 221 1 415 415
Estradiol ben- 5 M 345 389 1 457 509
zoate- 8.3y wkly. 6 F 296 346 1 453 500
Stilbestrol 5 M 116 148 1 249 281
250y wkly. 2 F 244 276 1 251 283
Estradiol benzoate 16.6y 8 M 256 284 1 455- 489
and testosterone pro- 6 F 232 264 .... ...... ......
pionate 1.25 mg. wkly.
were most pronounced at the periphery of the gland where very few
or no eosinophilic cells were present over considerable areas. The
central areas near the pars intermedia showed a more normal distri-
bution of the eosinophilic cells. Very few or no granular basophilic
cells were present even inthis area. Particularly in the lateral lobes
of the glands distended vascular sinuses widely separated the cell
cords. In all of these hypophyses the changes were of a general
hyperplastic nature.
The hypophyses weighing from 47 to 87 mg. presented a dif-
ferent histological picture. The greater portion of the glands con-
sisted of densely placed cords of uniformly enlarged chromophobic
cells and occasional hemorrhagic areas. The chromophobic cells
showed a characteristic radial arrangement around the larger vessels.
Mitotic figures were frequently found. Relatively clear areas larger
than the nuclei were present in the cytoplasm of the tumor cells
(Fig. 4). These areas were considered as possible negative Golgi
images. A few eosinophilic cells were observed near the pars ner-
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vosa of the one hypophysis weighing 47 mg., though the greater
part of the gland was composed of dense hyperplastic tissue. Areas
of gland of normal structure were not found in the large tumors.
Evidence of invasion of the surrounding tissues was lacking. Pieces
of one tumor (Fig. 3) were grafted subcutaneously in 3 mice of the
same strain, but they failed to grow.
Extensive hypophyseal hyperplasias and adenomas appeared
relatively more frequently in male than in female mice, probably
because of the greater average survival period in the males. Many
female mice died with pyometra after comparatively brief estrogenic
treatment. The one female which lived for 415 days and which
received 16.6y of estradiol benzoate weekly had been hysterecto-
mized prior to starting the injections. The extreme hypophyseal
enlargements appeared in mice which tolerated treatment for from
80 to nearly 200 days longer than the average life of all mice in each
series (Table 1).
Smaller amounts of estradiol benzoate (8.3y weekly) were less
toxic; the average survival was from 90 to 120 days longer than in
mice receiving twice as much estrogen (Table 1). One adenoma
(63.5 mg.) and one marked hypophyseal hypertrophy (17.5 mg.)
appeared in 2 of the 11 mice receiving the smaller amounts for 457
and 453 days.
Two of the 7 mice of the C57 strain given weekly injections of
250y of stilbestrol had greatly enlarged hypophyses (26.5 and 17
mg.) after periods of 249 to 251 days (Table 1). The glands of
these animals were similar to those described above.
One of the 14 mice given weekly injections of 16.6y of estradiol
benzoate and testosterone propionate also showed a pituitary tumor
similar to those of mice receiving estrogens alone. Likewise, the
average survival time was quite similar to that of mice receiving
estrogens alone.
Larger doses of estrogens were entirely ineffective in inducing
marked hypophyseal hypertrophy, probably because of the reduced
survival period. The largest glands in mice receiving 50y of estra-
diol benzoate or estradiol dipropionate weighed 4 mg.
Discussion
The formation of hypophyseal tumors following the injection
of estrogens in rats or mice cannot be considered a new observation.
The variable observations reported from several laboratories in
which mice were used indicated that some factor or factors associated
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with the strain (genetic factors) or management (food and care)
might alter the response to relatively comparable hormonal
treatment.
The existence of genetic or at least strain-limited factors in the
appearance ofmammarytumors5 and testicular interstitial-cell hyper-
trophy3 in mice treated with estrogens has already been shown. The
strain-limited response of the pituitary gland may now also be added
to this list.
The strains of mice used in this study were initially selected and
inbred for the tendency to develop or fail to develop mammary
tumors. The C57 strain in this laboratory has a very low incidence
of spontaneous mammary tumors. None of the 106 mice used in
the present study developed such tumors. However, the tendency
to develop mammary tumors cannot be associated with the absence
of the tendency to develop hypophyseal tumors, since in other labo-
ratories high-mammary-tumor strains have developed hypophyseal
hyperplasia and adenomas.'0 Likewise, in this laboratory other very
low-mammary-tumor strains (N and JK) have not developed
tumors of the hypophysis following the injections of comparable
amounts of estrogens.
The adrenals of mice of the C57 strain showed extreme "brown
degeneration" following the injection of estrogens. Though these
changes might be associated with the tendency to develop hypophy-
seal lesions, theycould not be associated with the tendency to develop
mammary tumors. The responses of the hypophyses as well as of
the mammaryglands, testes, and adrenals tended to vary in different
strains of mice and independently of one another.
Mammary growth cannot be considered independent of the
pituitary gland at this time. In the absence of the hypophysis the
mammary glands of mice did not develop following the injection of
estrogen.8 Large amounts of estrogen partially inhibited mammary
growth7 as well as body growth."3 It has been assumed that both
of these changes are indirect, being mediated through the pituitary
gland. Although strain variations have been shown in the develop-
mentofhyperplasticchanges ofthepituitaryinestrogen-treatedmice,
the functional hypophyseal-mammary relationships have been simi-
lar in all strains as far as has been determined. The mammary
glands of mice of the low-mammary-tumor JK and N strains
responded in much the same way as those of the C57 strain, although
the latter did not develop hypophyseal tumors. The glands of mice
of the tumor-susceptible strains cannot be satisfactorily compared
with those of the resistant strains.
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The effects of dose within the ranges used indicated, as pre-
viously suggested, that the duration of treatment rather than the
amount (excluding amounts not satisfactorily tolerated) is of greater
significance. Pyometra, urine retention with an associated extreme
hydronephrosis, and extensive hemorrhages along the large abdomi-
nal or thoracic vessels were the most common causes of death in mice
ofthe C57 strain. These conditions occurred at an earlier age in mice
receiving the larger doses of hormone.
Summary
Hypophyseal adenomas did not appear in over 700 mice of 6
inbred strains (A, C3H, CBA, C12I, JK, and N) following the injec-
tion of one of several estrogens for prolonged periods. The glands
rarely weighed more than 4 mg.
Fifteen of 106 mice of the C57 strain similarly treated had pitui-
tary glands weighing over 12 mg. The pituitary glands weighing
less than 26 mg. showed a generalized hypertrophy of the chromo-
phobe cells and distension of the vascular sinuses. Glands weighing
from 47 to 87 mg. consisted largely of adenomas of non-granular
chromophobic cells.
Mice of the C57 strain showed extensive brown degeneration of
the adrenal which may be related to the hypophyseal changes.
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FIGS. 1-3. Opened skulls of mice showing hypophyseal adenomas and a hypertro-
phied hypophysis as observed at autopsy. X 3 approximately.
1. Adenoma of the pituitary gland weighing 53.5 mg. in a male mouse of the C57
strain. Treatment: 16.6-y estradiol weekly (960y in 389 days) starting at 59
days. The arrow indicates the right border of the tumor.
2. Hypertrophied pituitary gland of a CBA-strain mouse (4.5 mg.). Treatment:
16.6-y estradiol benzoate weekly for 389 days.
3. Hypophyseal adenoma (87 mg.) in a C5U-strain mouse. Treatment: 16.6-y
estradiol benzoate weekly (813'y in 343 days), starting at 28 days. The stippled
line marks the border of the tumor.
FIG. 4. Section of the chromophobe adenoma shown in Fig. 3 above.